An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy ...

Shandong Boan Biotechnology Company., Limited. Class H ( ($HK:6955) ) has shared an update. Shandong Boan Biotechnology Co., Ltd. has received ...

GLP-1 RA use increases risk for nonarteritic anterior ischemic optic neuropathy compared with other second-line antidiabetic medications.

Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2025 Earnings Conference Call. [Operator ...

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.